## Andreas L Birkenfeld

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/7854768/andreas-l-birkenfeld-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

9,689 96 195 45 h-index g-index citations papers 6.53 225 13,552 7.9 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
195	Endoplasmic reticulum stress and the unfolded protein response in skeletal muscle of subjects suffering from peritoneal sepsis <i>Scientific Reports</i> , <b>2022</b> , 12, 504	4.9	O
194	Metabolic implications of pancreatic fat accumulation. <i>Nature Reviews Endocrinology</i> , <b>2022</b> , 18, 43-54	15.2	2
193	The German Gestational Diabetes Study (PREG), a prospective multicentre cohort study: rationale, methodology and design <i>BMJ Open</i> , <b>2022</b> , 12, e058268	3	0
192	Sodium retention in nephrotic syndrome is independent of the activation of the membrane-anchored serine protease prostasin (CAP1/PRSS8) and its enzymatic activity <i>Pflugers Archiv European Journal of Physiology</i> , <b>2022</b> , 1	4.6	2
191	Proteolytic activation of the epithelial sodium channel (ENaC) by factor VII activating protease (FSAP) and its relevance for sodium retention in nephrotic mice. <i>Pflugers Archiv European Journal of Physiology</i> , <b>2021</b> , 474, 217	4.6	6
190	Reproducibility and discrimination of different indices of insulin sensitivity and insulin secretion. <i>PLoS ONE</i> , <b>2021</b> , 16, e0258476	3.7	0
189	Elevated circulating follistatin associates with an increased risk of type 2 diabetes. <i>Nature Communications</i> , <b>2021</b> , 12, 6486	17.4	2
188	Slow deep breathing modulates cardiac vagal activity but does not affect peripheral glucose metabolism in healthy men. <i>Scientific Reports</i> , <b>2021</b> , 11, 20306	4.9	1
187	Diabetes mellitus und Herz. <i>Diabetologie Und Stoffwechsel</i> , <b>2021</b> , 16, S319-S323	0.7	O
186	COVID-19 and metabolic disease: mechanisms and clinical management. <i>Lancet Diabetes and Endocrinology,the</i> , <b>2021</b> , 9, 786-798	18.1	33
185	Empagliflozin Improves Insulin Sensitivity of the Hypothalamus in Humans With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial. <i>Diabetes Care</i> , <b>2021</b> ,	14.6	3
184	Renal effects of the serine protease inhibitor aprotinin in healthy conscious mice. <i>Acta Pharmacologica Sinica</i> , <b>2021</b> ,	8	4
183	Zymogen-locked mutant prostasin (Prss8) leads to incomplete proteolytic activation of the epithelial sodium channel (ENaC) and severely compromises triamterene tolerance in mice. <i>Acta Physiologica</i> , <b>2021</b> , 232, e13640	5.6	8
182	Diabetes und nicht-alkoholische Fettleber-Erkrankungen. Diabetes Aktuell, <b>2021</b> , 19, 67-70	О	
181	Improving insulin sensitivity, liver steatosis and fibrosis in type 2 diabetes by food-based digital education-assisted lifestyle intervention program: a feasibility study. <i>European Journal of Nutrition</i> , <b>2021</b> , 60, 3811-3818	5.2	1
180	Effects of Insoluble Cereal Fibre on Body Fat Distribution in the Optimal Fibre Trial. <i>Molecular Nutrition and Food Research</i> , <b>2021</b> , 65, e2000991	5.9	1
179	Hemostatic alterations linked to body fat distribution, fatty liver, and insulin resistance. <i>Molecular Metabolism</i> , <b>2021</b> , 53, 101262	8.8	5

178	Therapie des Typ-2-Diabetes. <i>Diabetologe</i> , <b>2021</b> , 17, 422	0.2	
177	Diabetes mellitus und Herz. <i>Diabetologe</i> , <b>2021</b> , 17, 448-451	0.2	
176	Pancreatic fat cells of humans with type 2 diabetes display reduced adipogenic and lipolytic activity. <i>American Journal of Physiology - Cell Physiology</i> , <b>2021</b> , 320, C1000-C1012	5.4	1
175	Determinants of hepatic insulin clearance - Results from a Mendelian Randomization study. <i>Metabolism: Clinical and Experimental</i> , <b>2021</b> , 119, 154776	12.7	1
174	A Narrative Review on the Role of AMPK on De Novo Lipogenesis in Non-Alcoholic Fatty Liver Disease: Evidence from Human Studies. <i>Cells</i> , <b>2021</b> , 10,	7.9	6
173	Dose-dependent effects of insoluble fibre on glucose metabolism: a stratified post hoc analysis of the Optimal Fibre Trial (OptiFiT). <i>Acta Diabetologica</i> , <b>2021</b> , 58, 1649-1658	3.9	1
172	Plasminogen deficiency does not prevent sodium retention in a genetic mouse model of experimental nephrotic syndrome. <i>Acta Physiologica</i> , <b>2021</b> , 231, e13512	5.6	12
171	Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes. <i>Nature Medicine</i> , <b>2021</b> , 27, 49-57	50.5	68
170	The longevity gene mIndy (I@n Not Dead, Yet) affects blood pressure through sympathoadrenal mechanisms. <i>JCI Insight</i> , <b>2021</b> , 6,	9.9	2
169	Low-fat hypocaloric diet reduces neprilysin in overweight and obese human subjects. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 938-942	3.7	1
168	Consequences of the COVID-19 pandemic for patients with metabolic diseases. <i>Nature Metabolism</i> , <b>2021</b> , 3, 289-292	14.6	17
167	Intraperitoneal extension of the peritoneal dialysis catheter-a new technique for catheter implantation in patients with obesity. <i>Journal of Nephrology</i> , <b>2021</b> , 1	4.8	O
166	Deletion of the diabetes candidate gene Slc16a13 in mice attenuates diet-induced ectopic lipid accumulation and insulin resistance. <i>Communications Biology</i> , <b>2021</b> , 4, 826	6.7	2
165	Free fatty acids, glicentin and glucose-dependent insulinotropic polypeptide as potential major determinants of fasting substrate oxidation. <i>Scientific Reports</i> , <b>2021</b> , 11, 16642	4.9	1
164	Different Effects of Lifestyle Intervention in High- and Low-Risk Prediabetes: Results of the Randomized Controlled Prediabetes Lifestyle Intervention Study (PLIS). <i>Diabetes</i> , <b>2021</b> , 70, 2785-2795	0.9	5
163	Proteinuric chronic kidney disease is associated with altered red blood cell lifespan, deformability and metabolism. <i>Kidney International</i> , <b>2021</b> , 100, 1227-1239	9.9	7
162	Essential role of DNA-PKcs and plasminogen for the development of doxorubicin-induced glomerular injury in mice. <i>DMM Disease Models and Mechanisms</i> , <b>2021</b> , 14,	4.1	2
161	Experimental nephrotic syndrome leads to proteolytic activation of the epithelial Na channel in the mouse kidney. <i>American Journal of Physiology - Renal Physiology</i> , <b>2021</b> , 321, F480-F493	4.3	6

160	Neue Subtypen bei Prdiabetes. <i>Diabetologe</i> , <b>2021</b> , 17, 26-31	0.2	
159	Global pandemics interconnected - obesity, impaired metabolic health and COVID-19. <i>Nature Reviews Endocrinology</i> , <b>2021</b> , 17, 135-149	15.2	140
158	The Role of Physical Activity in Nonalcoholic and Metabolic Dysfunction Associated Fatty Liver Disease <i>Biomedicines</i> , <b>2021</b> , 9,	4.8	1
157	Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial. <i>Diabetes Care</i> , <b>2020</b> , 43, 1085-1093	14.6	33
156	Human Prostate Cancer is Characterized by an Increase in Urea Cycle Metabolites. <i>Cancers</i> , <b>2020</b> , 12,	6.6	12
155	Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. <i>Lancet Diabetes and Endocrinology,the</i> , <b>2020</b> , 8, 301-312	18.1	75
154	Obesity and impaired metabolic health in patients with COVID-19. <i>Nature Reviews Endocrinology</i> , <b>2020</b> , 16, 341-342	15.2	303
153	Practical recommendations for the management of diabetes in patients with COVID-19. <i>Lancet Diabetes and Endocrinology,the</i> , <b>2020</b> , 8, 546-550	18.1	463
152	Therapie des Typ-2-Diabetes. <i>Diabetologe</i> , <b>2020</b> , 16, 266-287	0.2	
151	Lipidtherapie bei Patienten mit Diabetes mellitus Œine gemeinsame Stellungnahme der Kommission Fettstoffwechsel sowie der AG Herz und Diabetes der Deutschen Diabetes Gesellschaft (DDG), der Sektion Diabetologie und Stoffwechsel der Deutschen Gesellschaft fd	0.7	1
150	Diabetes mellitus und Herz. <i>Diabetologie Und Stoffwechsel</i> , <b>2020</b> , 15, S166-S169	0.7	
149	150-OR: Brain Insulin Sensitivity Is Modulated by Menstrual Cycle. <i>Diabetes</i> , <b>2020</b> , 69, 150-OR	0.9	Ο
148	1856-P: Hepatic Insulin Clearance Is Not Driven by Liver Fat but by Systemic Inflammation: A Mendelian Randomization Study. <i>Diabetes</i> , <b>2020</b> , 69, 1856-P	0.9	1
147	1654-P: Deletion of the Mammalian Indy Homolog (Slc13a5) Improves Hepatic Insulin Sensitivity through Vagal Nerve Signaling. <i>Diabetes</i> , <b>2020</b> , 69, 1654-P	0.9	
146	102-OR: Detection of Diabetes from Whole-Body Magnetic Resonance Imaging Using Deep Learning. <i>Diabetes</i> , <b>2020</b> , 69, 102-OR	0.9	0
145	1324-P: GLP-1 Hypersecretion in Gestational Diabetes. <i>Diabetes</i> , <b>2020</b> , 69, 1324-P	0.9	
144	Therapie des Typ-2-Diabetes. <i>Diabetologie Und Stoffwechsel</i> , <b>2020</b> , 15, S65-S92	0.7	8
143	Solute Carrier Transporters as Potential Targets for the Treatment of Metabolic Disease. <i>Pharmacological Reviews</i> , <b>2020</b> , 72, 343-379	22.5	44

142	Positionspapier zur Lipidtherapie bei Patienten mit Diabetes mellitus. <i>Diabetologe</i> , <b>2020</b> , 16, 74-78	0.2	
141	FFA2-, but not FFA3-agonists inhibit GSIS of human pseudoislets: a comparative study with mouse islets and rat INS-1E cells. <i>Scientific Reports</i> , <b>2020</b> , 10, 16497	4.9	5
140	Disruption of the sodium-dependent citrate transporter SLC13A5 in mice causes alterations in brain citrate levels and neuronal network excitability in the hippocampus. <i>Neurobiology of Disease</i> , <b>2020</b> , 143, 105018	7.5	9
139	Normalized Indices Derived from Visceral Adipose Mass Assessed by Magnetic Resonance Imaging and Their Correlation with Markers for Insulin Resistance and Prediabetes. <i>Nutrients</i> , <b>2020</b> , 12,	6.7	3
138	Nutritional and metabolic regulation of the metabolite dimethylguanidino valeric acid: an early marker of cardiometabolic disease. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2020</b> , 319, E509-E518	6	4
137	Increased Expressions of Matrix Metalloproteinases (MMPs) in Prostate Cancer Tissues of Men with Type 2 Diabetes. <i>Biomedicines</i> , <b>2020</b> , 8,	4.8	4
136	Increased Hepatic ACE2 Expression in NAFL and Diabetes-A Risk for COVID-19 Patients?. <i>Diabetes Care</i> , <b>2020</b> , 43, e134-e136	14.6	17
135	Benefit/risk profile of dapagliflozin 5 mg in the DEPICT-1 and -2 trials in individuals with type 1 diabetes and body mass index 27 kg/m. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 2151-2160	6.7	9
134	Characterization of Hormone-Dependent Pathways in Six Human Prostate-Cancer Cell Lines: A Gene-Expression Study. <i>Genes</i> , <b>2020</b> , 11,	4.2	2
133	Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 2219-2229	59.2	347
132	Investigating obesity-associated brain inflammation using quantitative water content mapping. Journal of Neuroendocrinology, <b>2020</b> , 32, e12907	3.8	5
132		3.8	5
	Journal of Neuroendocrinology, <b>2020</b> , 32, e12907  Transcript Levels of Aldo-Keto Reductase Family 1 Subfamily C (AKR1C) Are Increased in Prostate		
131	Journal of Neuroendocrinology, 2020, 32, e12907  Transcript Levels of Aldo-Keto Reductase Family 1 Subfamily C (AKR1C) Are Increased in Prostate Tissue of Patients with Type 2 Diabetes. Journal of Personalized Medicine, 2020, 10,  Considering Insulin Secretory Capacity as Measured by a Fasting C-Peptide/Glucose Ratio in Selecting Glucose-Lowering Medications. Experimental and Clinical Endocrinology and Diabetes,	3.6	3
131	Transcript Levels of Aldo-Keto Reductase Family 1 Subfamily C (AKR1C) Are Increased in Prostate Tissue of Patients with Type 2 Diabetes. <i>Journal of Personalized Medicine</i> , <b>2020</b> , 10,  Considering Insulin Secretory Capacity as Measured by a Fasting C-Peptide/Glucose Ratio in Selecting Glucose-Lowering Medications. <i>Experimental and Clinical Endocrinology and Diabetes</i> , <b>2020</b> ,  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. <i>New England Journal of</i>	3.6	2
131 130 129	Transcript Levels of Aldo-Keto Reductase Family 1 Subfamily C (AKR1C) Are Increased in Prostate Tissue of Patients with Type 2 Diabetes. <i>Journal of Personalized Medicine</i> , <b>2020</b> , 10,  Considering Insulin Secretory Capacity as Measured by a Fasting C-Peptide/Glucose Ratio in Selecting Glucose-Lowering Medications. <i>Experimental and Clinical Endocrinology and Diabetes</i> , <b>2020</b> ,  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 1413-1424	3.6 2.3 59.2	2
131 130 129 128	Transcript Levels of Aldo-Keto Reductase Family 1 Subfamily C (AKR1C) Are Increased in Prostate Tissue of Patients with Type 2 Diabetes. Journal of Personalized Medicine, 2020, 10,  Considering Insulin Secretory Capacity as Measured by a Fasting C-Peptide/Glucose Ratio in Selecting Glucose-Lowering Medications. Experimental and Clinical Endocrinology and Diabetes, 2020,  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine, 2020, 383, 1413-1424  Materner Metabolismus und fetale Entwicklung. Diabetologe, 2020, 16, 647-653  Response of Mitochondrial Respiration in Adipose Tissue and Muscle to 8 Weeks of Endurance	3.6 2.3 59.2	3 2 1099

124	Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial. <i>Diabetes Care</i> , <b>2020</b> , 43, 298-305	14.6	86
123	deletion causes extensive vacuolation that consumes the insulin content of pancreatic Itells.  Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 19983-1998	8 <sup>11.5</sup>	12
122	Response to Letter to the Editor: "Incidence of Hypoglycemia After Gastric Bypass vs Sleeve Gastrectomy: A Randomized Trial". <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> , 104, 732-733	3 <sup>5.6</sup>	1
121	Improved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials. <i>Diabetes, Obesity and Metabolism,</i> <b>2019</b> , 21, 2315-2326	6.7	7
120	Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 841-851	59.2	567
119	Lipid Profiles in Lyme Borreliosis: A Potential Role for Apheresis?. <i>Hormone and Metabolic Research</i> , <b>2019</b> , 51, 326-329	3.1	4
118	Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2019</b> , 321, 1466-1480	27.4	138
117	Beta-Aminoisobutyric Acid as a Novel Regulator of Carbohydrate and Lipid Metabolism. <i>Nutrients</i> , <b>2019</b> , 11,	6.7	37
116	Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. <i>New England Journal of Medicine</i> , <b>2019</b> , 380, 1022-1032	59.2	265
115	Myocardial metabolism in heart failure: Purinergic signalling and other metabolic concepts. <i>Pharmacology &amp; Therapeutics</i> , <b>2019</b> , 194, 132-144	13.9	24
114	Are Lifestyle Therapies Effective for NAFLD Treatment?. <i>Trends in Endocrinology and Metabolism</i> , <b>2019</b> , 30, 701-709	8.8	51
113	Positionspapier zur Lipidtherapie bei Patienten mit Diabetes mellitus. <i>Diabetologe</i> , <b>2019</b> , 15, 432-436	0.2	1
112	Fasting Glucose State Determines Metabolic Response to Supplementation with Insoluble Cereal Fibre: A Secondary Analysis of the Optimal Fibre Trial (OptiFiT). <i>Nutrients</i> , <b>2019</b> , 11,	6.7	13
111	Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. <i>American Journal of Nephrology</i> , <b>2019</b> , 50, 345-356	4.6	80
110	Progress trotz Lipoproteinapherese. <i>CardioVasc</i> , <b>2019</b> , 19, 27-28	O	
109	Therapie des Typ-2-Diabetes. <i>Diabetologie Und Stoffwechsel</i> , <b>2019</b> , 14, S167-S187	0.7	19
108	Obesity Does Not Modulate the Glycometabolic Benefit of Insoluble Cereal Fibre in Subjects with Prediabetes-A Stratified Post Hoc Analysis of the Optimal Fibre Trial (OptiFiT). <i>Nutrients</i> , <b>2019</b> , 11,	6.7	8
107	Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. <i>American Journal of Nephrology</i> , <b>2019</b> , 50, 333-344	4.6	70

106	111-LB: Oral Semaglutide vs. Sitagliptin: Efficacy by Baseline HbA1c and Background OAD in PIONEER 3. <i>Diabetes</i> , <b>2019</b> , 68, 111-LB	0.9	1
105	Positionspapier zur Lipidtherapie bei Patienten mit Diabetes mellitus. <i>Diabetologie Und Stoffwechsel</i> , <b>2019</b> , 14, S226-S231	0.7	1
104	Therapy of Type 2 Diabetes. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, S73-S92	2.3	12
103	New insight into the mechanisms of ectopic fat deposition improvement after bariatric surgery. <i>Scientific Reports</i> , <b>2019</b> , 9, 17315	4.9	14
102	Actual situation of lipoprotein apheresis in patients with elevated lipoprotein(a) levels. <i>Atherosclerosis Supplements</i> , <b>2019</b> , 40, 1-7	1.7	9
101	Cardiovascular risk factors in patients with premature cardiovascular events attending the University of Dresden Lipid Clinic. <i>Atherosclerosis Supplements</i> , <b>2019</b> , 40, 94-99	1.7	2
100	Position Paper on Lipid Therapy in Patients with Diabetes Mellitus. <i>Experimental and Clinical Endocrinology and Diabetes</i> , <b>2019</b> , 127, S97-S101	2.3	
99	Metabolic Syndrome is a Risk Factor for Post-Operative Adhesions: Need for Novel Treatment Strategies. <i>Hormone and Metabolic Research</i> , <b>2019</b> , 51, 35-41	3.1	6
98	Fibre supplementation for the prevention of type 2 diabetes and improvement of glucose metabolism: the randomised controlled Optimal Fibre Trial (OptiFiT). <i>Diabetologia</i> , <b>2018</b> , 61, 1295-1305	10.3	22
97	Incidence of Hypoglycemia After Gastric Bypass vs Sleeve Gastrectomy: A Randomized Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2018</b> , 103, 2136-2146	5.6	48
96	Intensive lifestyle modifications with or without liraglutide 3mg vs. sleeve gastrectomy: A three-arm non-randomised, controlled, pilot study. <i>Diabetes and Metabolism</i> , <b>2018</b> , 44, 235-242	5.4	15
95	Urinary Lipidomics: evidence for multiple sources and sexual dimorphism in healthy individuals. <i>Pharmacogenomics Journal</i> , <b>2018</b> , 18, 331-339	3.5	5
94	Reply. <i>Hepatology</i> , <b>2018</b> , 67, 452-453	11.2	
93	The longevity gene INDY (I <b>©</b> n Not Dead Yet) in metabolic control: Potential as pharmacological target. <i>Pharmacology &amp; Therapeutics</i> , <b>2018</b> , 185, 1-11	13.9	23
92	Analysis of naturally occurring mutations in the human uptake transporter NaCT important for bone and brain development and energy metabolism. <i>Scientific Reports</i> , <b>2018</b> , 8, 11330	4.9	9
91	© ell-specific deletion of guanylyl cyclase A, the receptor for atrial natriuretic peptide, accelerates obesity-induced glucose intolerance in mice. <i>Cardiovascular Diabetology</i> , <b>2018</b> , 17, 103	8.7	3
90	Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial. <i>Diabetes Care</i> , <b>2018</b> , 41, 1938-1	9 <sup>1</sup> 46 <sup>6</sup>	141
89	Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. The 2018, 392, 637-649	40	242

88	Neuronal Deletion of the Mammalian Indy Homolog (Slc13a5) Increases Energy Expenditure in Mice. <i>Diabetes</i> , <b>2018</b> , 67, 1804-P	0.9	
87	Positionspapier zur Lipidtherapie bei Patienten mit Diabetes mellitus. Aktuelle Kardiologie, <b>2018</b> , 7, 431	-43:5	
86	Intravenous Ferric Carboxymaltose in Patients with Type 2 Diabetes Mellitus and Iron Deficiency: CLEVER Trial Study Design and Protocol. <i>Diabetes Therapy</i> , <b>2018</b> , 9, 37-47	3.6	2
85	Positionspapier zur Lipidtherapie bei Patienten mit Diabetes mellitus. <i>Diabetologie Und Stoffwechsel</i> , <b>2018</b> , 13, S209-S213	0.7	2
84	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. <i>Lancet, The</i> , <b>2018</b> , 392, 1519-1529	40	771
83	Effect of Magnesium Loading Dose on Insulin Resistance in Patients With Stress-Induced Hyperglycemia: A Randomized Clinical Trial. <i>Journal of Intensive Care Medicine</i> , <b>2018</b> , 885066618803866	; 3.3	1
82	The anorexigenic peptide neurotensin relates to insulin sensitivity in obese patients after BPD or RYGB metabolic surgery. <i>International Journal of Obesity</i> , <b>2018</b> , 42, 2057-2061	5.5	9
81	Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes. <i>Diabetic Medicine</i> , <b>2018</b> , 35, 1375-1382	3.5	19
80	Natriuretic Peptides in Cardiovascular and Metabolic Crosstalk: Implications for Hypertension Management. <i>Hypertension</i> , <b>2018</b> , 72, 270-276	8.5	30
79	The human longevity gene homolog INDY and interleukin-6 interact in hepatic lipid metabolism. <i>Hepatology</i> , <b>2017</b> , 66, 616-630	11.2	33
78	Regulation of body weight and energy homeostasis by neuronal cell adhesion molecule 1. <i>Nature Neuroscience</i> , <b>2017</b> , 20, 1096-1103	25.5	29
77	ANGPTL8 (Betatrophin) is Expressed in Visceral Adipose Tissue and Relates to Human Hepatic Steatosis in Two Independent Clinical Collectives. <i>Hormone and Metabolic Research</i> , <b>2017</b> , 49, 343-349	3.1	16
76	Intra-individual variability and circadian rhythm of vascular endothelial growth factors in subjects with normal glucose tolerance and type 2 diabetes. <i>PLoS ONE</i> , <b>2017</b> , 12, e0184234	3.7	7
75	Retinol saturase coordinates liver metabolism by regulating ChREBP activity. <i>Nature Communications</i> , <b>2017</b> , 8, 384	17.4	17
74	Glucagon Decreases IGF-1 Bioactivity in Humans, Independently of Insulin, by Modulating Its Binding Proteins. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2017</b> , 102, 3480-3490	5.6	6
73	Increased lipogenesis in spite of upregulated hepatic 5@MP-activated protein kinase in human non-alcoholic fatty liver. <i>Hepatology Research</i> , <b>2017</b> , 47, 890-901	5.1	15
72	Insulin-Like Growth Factor (IGF) Binding Protein-2, Independently of IGF-1, Induces GLUT-4 Translocation and Glucose Uptake in 3T3-L1 Adipocytes. <i>Oxidative Medicine and Cellular Longevity</i> , <b>2017</b> , 2017, 3035184	6.7	19
71	Pharmacogenomics in type 2 diabetes: oral antidiabetic drugs. <i>Pharmacogenomics Journal</i> , <b>2016</b> , 16, 39	9 <sub>3</sub> 4510	14

70	Hypophosphatemia promotes lower rates of muscle ATP synthesis. FASEB Journal, 2016, 30, 3378-3387	0.9	45
69	Adipocyte-specific blockade of gamma-secretase, but not inhibition of Notch activity, reduces adipose insulin sensitivity. <i>Molecular Metabolism</i> , <b>2016</b> , 5, 113-121	8.8	15
68	Fetuin A is a Predictor of Liver Fat in Preoperative Patients with Nonalcoholic Fatty Liver Disease. Journal of Investigative Surgery, <b>2016</b> , 29, 266-74	1.2	16
67	The role of immune cells in metabolism-related liver inflammation and development of non-alcoholic steatohepatitis (NASH). <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2016</b> , 17, 29-39	10.5	80
66	Chemerin in peritoneal sepsis and its associations with glucose metabolism and prognosis: a translational cross-sectional study. <i>Critical Care</i> , <b>2016</b> , 20, 39	10.8	14
65	Cardiometabolic crosstalk in obesity-associated arterial hypertension. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2016</b> , 17, 19-28	10.5	11
64	The longevity transporter mIndy (Slc13a5) as a target for treating hepatic steatosis and insulin resistance. <i>Aging</i> , <b>2016</b> , 8, 208-9	5.6	8
63	Serum and Plasma Levels of Vascular Endothelial Growth Factors in Relation to Quality of Glucose Control, Biomarkers of Inflammation, and Diabetic Nephropathy. <i>Hormone and Metabolic Research</i> , <b>2016</b> , 48, 529-34	3.1	20
62	Comment on Ferrannini et al. CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. Diabetes Care 2016;39:1108-1114. <i>Diabetes Care</i> , <b>2016</b> , 39, e224-e225	14.6	2
61	The metabolic vascular syndrome - guide to an individualized treatment. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2016</b> , 17, 5-17	10.5	25
60	Determinants of mortality in patients with type 2 diabetes: a review. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2016</b> , 17, 129-37	10.5	22
59	Inhibition of citrate cotransporter Slc13a5/mINDY by RNAi improves hepatic insulin sensitivity and prevents diet-induced non-alcoholic fatty liver disease in mice. <i>Molecular Metabolism</i> , <b>2016</b> , 5, 1072-108	3 <sup>8.8</sup>	22
58	Risk of and risk factors for hypoglycemia and associated arrhythmias in patients with type 2 diabetes and cardiovascular disease: a cohort study under real-world conditions. <i>Acta Diabetologica</i> , <b>2015</b> , 52, 889-95	3.9	53
57	Arylhydrocarbon receptor-dependent mIndy (Slc13a5) induction as possible contributor to benzo[a]pyrene-induced lipid accumulation in hepatocytes. <i>Toxicology</i> , <b>2015</b> , 337, 1-9	4.4	16
56	INTERACTING DISCIPLINES: Cardiac natriuretic peptides and obesity: perspectives from an endocrinologist and a cardiologist. <i>Endocrine Connections</i> , <b>2015</b> , 4, R25-36	3.5	23
55	Enhanced insulin signaling in density-enhanced phosphatase-1 (DEP-1) knockout mice. <i>Molecular Metabolism</i> , <b>2015</b> , 4, 325-36	8.8	18
54	Differential response of the natriuretic peptide system to weight loss and exercise in overweight or obese patients. <i>Journal of Hypertension</i> , <b>2015</b> , 33, 1458-64	1.9	28
53	Nutritional strategy to prevent fatty liver and insulin resistance independent of obesity by reducing glucose-dependent insulinotropic polypeptide responses in mice. <i>Diabetologia</i> , <b>2015</b> , 58, 374-83	10.3	27

52	Knockdown of Indy/CeNac2 extends Caenorhabditis elegans life span by inducing AMPK/aak-2. <i>Aging</i> , <b>2015</b> , 7, 553-67	5.6	18
51	Prevention of diet-induced hepatic steatosis and hepatic insulin resistance by second generation antisense oligonucleotides targeted to the longevity gene mIndy (Slc13a5). <i>Aging</i> , <b>2015</b> , 7, 1086-93	5.6	24
50	Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. <i>Hepatology</i> , <b>2014</b> , 59, 713-23	11.2	427
49	Metabolic actions of natriuretic peptides and therapeutic potential in the metabolic syndrome. <i>Pharmacology &amp; Therapeutics</i> , <b>2014</b> , 144, 12-27	13.9	89
48	The mammalian INDY homolog is induced by CREB in a rat model of type 2 diabetes. <i>Diabetes</i> , <b>2014</b> , 63, 1048-57	0.9	29
47	Muscle-specific activation of Ca(2+)/calmodulin-dependent protein kinase IV increases whole-body insulin action in mice. <i>Diabetologia</i> , <b>2014</b> , 57, 1232-41	10.3	7
46	Mitochondrial GTP insensitivity contributes to hypoglycemia in hyperinsulinemia hyperammonemia by inhibiting glucagon release. <i>Diabetes</i> , <b>2014</b> , 63, 4218-29	0.9	14
45	Comment on Boden et al. Insulin regulates the unfolded protein response in human adipose tissue. Diabetes 2014;63:912-922. <i>Diabetes</i> , <b>2014</b> , 63, e1	0.9	1
44	Pigment epithelium-derived factor (PEDF) suppresses IL-1Emediated c-Jun N-terminal kinase (JNK) activation to improve hepatocyte insulin signaling. <i>Endocrinology</i> , <b>2014</b> , 155, 1373-85	4.8	26
43	The flavones apigenin and luteolin induce FOXO1 translocation but inhibit gluconeogenic and lipogenic gene expression in human cells. <i>PLoS ONE</i> , <b>2014</b> , 9, e104321	3.7	40
42	Targeting pyruvate carboxylase reduces gluconeogenesis and adiposity and improves insulin resistance. <i>Diabetes</i> , <b>2013</b> , 62, 2183-94	0.9	86
41	The Role of INDY in Metabolic Regulation. <i>Computational and Structural Biotechnology Journal</i> , <b>2013</b> , 6, e201303020	6.8	25
40	Long-lasting improvements in liver fat and metabolism despite body weight regain after dietary weight loss. <i>Diabetes Care</i> , <b>2013</b> , 36, 3786-92	14.6	38
39	Elevated hepatic chemerin mRNA expression in human non-alcoholic fatty liver disease. <i>European Journal of Endocrinology</i> , <b>2013</b> , 169, 547-57	6.5	58
38	Comment on: Lazo et al. NH2-terminal pro-brain natriuretic peptide and risk of diabetes. Diabetes 2013;62:3189-3193. <i>Diabetes</i> , <b>2013</b> , 62, e28	0.9	1
37	Enhanced fasting glucose turnover in mice with disrupted action of TUG protein in skeletal muscle. <i>Journal of Biological Chemistry</i> , <b>2013</b> , 288, 20135-50	5.4	17
36	Insulin resistance is associated with elevated serum pigment epithelium-derived factor (PEDF) levels in morbidly obese patients. <i>Acta Diabetologica</i> , <b>2012</b> , 49 Suppl 1, S161-9	3.9	23
35	Acarbose treatment enhances mid-regional pro-atrial natriuretic peptide concentrations in non-diabetic individuals: further evidence for a common cardiometabolic pathway?. <i>Diabetologia</i> , <b>2012</b> , 55, 3392-5	10.3	5

34	Atrial natriuretic peptide and adiponectin interactions in man. PLoS ONE, 2012, 7, e43238	3.7	56
33	Comment on: Vila et al. B-type natriuretic peptide modulates ghrelin, hunger, and satiety in healthy men. Diabetes 2012;61:2592-2596. <i>Diabetes</i> , <b>2012</b> , 61, e22; author reply e23	0.9	6
32	Dissociation of inositol-requiring enzyme (IRE1∯mediated c-Jun N-terminal kinase activation from hepatic insulin resistance in conditional X-box-binding protein-1 (XBP1) knock-out mice. <i>Journal of Biological Chemistry</i> , <b>2012</b> , 287, 2558-67	5.4	118
31	Thiazolidinedione response in familial lipodystrophy patients with LMNA mutations: a case series. <i>Hormone and Metabolic Research</i> , <b>2012</b> , 44, 306-11	3.1	15
30	Natriuretic peptides enhance the oxidative capacity of human skeletal muscle. <i>Journal of Clinical Investigation</i> , <b>2012</b> , 122, 4675-9	15.9	127
29	Deletion of the mammalian INDY homolog mimics aspects of dietary restriction and protects against adiposity and insulin resistance in mice. <i>Cell Metabolism</i> , <b>2011</b> , 14, 184-95	24.6	145
28	Knockdown of the gene encoding Drosophila tribbles homologue 3 (Trib3) improves insulin sensitivity through peroxisome proliferator-activated receptor-[[PPAR-]] activation in a rat model of insulin resistance. <i>Diabetologia</i> , <b>2011</b> , 54, 935-44	10.3	24
27	Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects. <i>Hepatology</i> , <b>2011</b> , 53, 1504-14	11.2	185
26	Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance. <i>Hepatology</i> , <b>2011</b> , 54, 1650-60	11.2	102
25	Inhibition of Notch signaling ameliorates insulin resistance in a FoxO1-dependent manner. <i>Nature Medicine</i> , <b>2011</b> , 17, 961-7	50.5	134
24	Metabolic actions could confound advantageous effects of combined angiotensin II receptor and neprilysin inhibition. <i>Hypertension</i> , <b>2011</b> , 57, e4-5	8.5	25
23	SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. <i>Diabetes</i> , <b>2011</b> , 60, 890-8	0.9	166
22	Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 5748-52	11.5	119
21	Influence of the hepatic eukaryotic initiation factor 2alpha (eIF2alpha) endoplasmic reticulum (ER) stress response pathway on insulin-mediated ER stress and hepatic and peripheral glucose metabolism. <i>Journal of Biological Chemistry</i> , <b>2011</b> , 286, 36163-70	5.4	53
20	Epigallocatechin-3-gallate and postprandial fat oxidation in overweight/obese male volunteers: a pilot study. <i>European Journal of Clinical Nutrition</i> , <b>2010</b> , 64, 704-13	5.2	50
19	A high-fat, ketogenic diet causes hepatic insulin resistance in mice, despite increasing energy expenditure and preventing weight gain. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2010</b> , 299, E808-15	6	137
18	Neurohumoral and metabolic response to exercise in water. <i>Hormone and Metabolic Research</i> , <b>2010</b> , 42, 334-9	3.1	19
17	Deletion of the alpha-arrestin protein Txnip in mice promotes adiposity and adipogenesis while preserving insulin sensitivity. <i>Diabetes</i> , <b>2010</b> , 59, 1424-34	0.9	106

16	Targeted expression of catalase to mitochondria prevents age-associated reductions in mitochondrial function and insulin resistance. <i>Cell Metabolism</i> , <b>2010</b> , 12, 668-74	24.6	245
15	Adipose overexpression of desnutrin promotes fatty acid use and attenuates diet-induced obesity. <i>Diabetes</i> , <b>2009</b> , 58, 855-66	0.9	136
14	Genetic influences on the pharmacokinetics of orally and intravenously administered digoxin as exhibited by monozygotic twins. <i>Clinical Pharmacology and Therapeutics</i> , <b>2009</b> , 86, 605-8	6.1	13
13	Atrial natriuretic peptide induces postprandial lipid oxidation in humans. <i>Diabetes</i> , <b>2008</b> , 57, 3199-204	0.9	96
12	Water drinking induces thermogenesis through osmosensitive mechanisms. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2007</b> , 92, 3334-7	5.6	66
11	Metabolic regulation: effects of natriuretic peptide interactions. <i>Expert Review of Endocrinology and Metabolism</i> , <b>2007</b> , 2, 607-614	4.1	4
10	Norepinephrine transporter inhibition prevents tilt-induced pre-syncope. <i>Journal of the American College of Cardiology</i> , <b>2006</b> , 48, 516-22	15.1	35
9	Beta-adrenergic and atrial natriuretic peptide interactions on human cardiovascular and metabolic regulation. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2006</b> , 91, 5069-75	5.6	45
8	Jaccoud@nephritis. Nephrology Dialysis Transplantation, 2005, 20, 654-6	4.3	5
7	Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patientssibutramine and blood pressure. <i>Clinical Autonomic Research</i> , <b>2005</b> , 15, 200-6	4.3	24
6	Plasma exchange for primary autoimmune autonomic failure. <i>New England Journal of Medicine</i> , <b>2005</b> , 353, 1585-90	59.2	101
5	Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2005</b> , 90, 3622-8	5.6	136
4	The phosphorus connectiona puzzling business. <i>Nephrology Dialysis Transplantation</i> , <b>2004</b> , 19, 1643-5	4.3	2
3	A paraganglioma parasitizing the left circumflex coronary artery. <i>American Journal of Medicine</i> , <b>2004</b> , 116, 787-8	2.4	1
2	Paradoxical effect of sibutramine on autonomic cardiovascular regulation. Circulation, 2002, 106, 2459-	<b>65</b> 6.7	73
1	Short-term variability of proton density fat fraction in pancreas and liver assessed by multi-echo chemical-shift encoding-based MRI at 3 T		1